1255 related articles for article (PubMed ID: 29500526)
1. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
2. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
Leslie WD; Martineau P; Bryanton M; Lix LM
Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
[TBL] [Abstract][Full Text] [Related]
3. Bone density, microarchitecture, and material strength in chronic kidney disease patients at the time of kidney transplantation.
Pérez-Sáez MJ; Herrera S; Prieto-Alhambra D; Vilaplana L; Nogués X; Vera M; Redondo-Pachón D; Mir M; Güerri R; Crespo M; Díez-Pérez A; Pascual J
Osteoporos Int; 2017 Sep; 28(9):2723-2727. PubMed ID: 28497224
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials.
Wang J; Yao M; Xu JH; Shu B; Wang YJ; Cui XJ
Osteoporos Int; 2016 May; 27(5):1683-90. PubMed ID: 26733377
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
6. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
7. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
8. Preoperative bone health assessment and optimization in spine surgery.
Anderson PA; Kadri A; Hare KJ; Binkley N
Neurosurg Focus; 2020 Aug; 49(2):E2. PubMed ID: 32738805
[TBL] [Abstract][Full Text] [Related]
9. Determinants of bone mineral density in stable kidney transplant recipients.
Gupta AK; Huang M; Prasad GV
J Nephrol; 2012; 25(3):373-83. PubMed ID: 21928224
[TBL] [Abstract][Full Text] [Related]
10. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
11. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
12. Fracture prediction from repeat BMD measurements in clinical practice.
Leslie WD; Brennan-Olsen SL; Morin SN; Lix LM
Osteoporos Int; 2016 Jan; 27(1):203-10. PubMed ID: 26243362
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma.
Dam TT; Harrison S; Fink HA; Ramsdell J; Barrett-Connor E;
Osteoporos Int; 2010 Aug; 21(8):1341-9. PubMed ID: 19816753
[TBL] [Abstract][Full Text] [Related]
14. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC
Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632
[TBL] [Abstract][Full Text] [Related]
15. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
16. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Ibach K; Preuss J
Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
[TBL] [Abstract][Full Text] [Related]
17. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
[TBL] [Abstract][Full Text] [Related]
18. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study.
Pichette V; Bonnardeaux A; Prudhomme L; Gagné M; Cardinal J; Ouimet D
Am J Kidney Dis; 1996 Jul; 28(1):105-14. PubMed ID: 8712204
[TBL] [Abstract][Full Text] [Related]
19. Trabecular bone score in kidney transplant recipients.
Naylor KL; Lix LM; Hans D; Garg AX; Rush DN; Hodsman AB; Leslie WD
Osteoporos Int; 2016 Mar; 27(3):1115-1121. PubMed ID: 26608055
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Shane E; Silverberg SJ; Donovan D; Papadopoulos A; Staron RB; Addesso V; Jorgesen B; McGregor C; Schulman L
Am J Med; 1996 Sep; 101(3):262-9. PubMed ID: 8873487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
